Viz.ai is the leader in applied artificial intelligence in healthcare. It was inspired by a patient who underwent a successful brain surgery and yet died because the surgery came too late.

Viz.ai’s mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care.

Viz.ai was founded in Israel in 2016 by Chris Mansi, David Golan and Manoj Ramachandran. The company is headquartered in San Francisco, California, with offices in Tel Aviv, Portugal and Amsterdam.

Viz.ai’s flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about suspected stroke patients straight to a specialist who can intervene and treat.

Viz.ai’s life science portfolio expands the power of the AI-powered Viz Platform to pharmaceutical and medical device companies who are leaning into digital transformation to bring life-saving therapies to market more efficiently.

Viz.ai’s comprehensive neurovascular and vascular AI platform is clinically proven to save time and improve patient outcomes and access to care. Viz covers more than 220 million lives across 1,300+ hospitals and health systems in the U.S. and Europe.

Viz is backed by Tiger Global, Insight Partners, Kleiner Perkins, Greenoaks, GV, Scale Venture Partners, Threshold, CIBC Innovation Banking, Innovation Endeavors, Sozo Ventures, CRV, Susa, and others. The company raised $40M in a growth round on Mar 22, 2023. This brings Viz's total funding to $291.6M to date. Viz was valued at a $1.2B in its previous $100M round in Apr 2022.